HIV Programmes and Advocacy, International AIDS Society, Cape Town, South Africa.
Centre for Infectious Disease Epidemiology and Research, University of Cape Town, Cape Town, South Africa.
J Int AIDS Soc. 2021 Jun;24(6):e25704. doi: 10.1002/jia2.25704.
INTRODUCTION: In response to COVID-19, national ministries of health adapted HIV service delivery guidelines to ensure uninterrupted access to antiretroviral therapy (ART) and limit the frequency of contact with health facilities. In this commentary, we summarize four ways in which differentiated service delivery (DSD) for HIV treatment has been accelerated during COVID-19 in policy and implementation in sub-Saharan Africa (SSA) - (i) expanding eligibility for DSD for HIV treatment, (ii) extending multi-month dispensing (MMD) and reducing the frequency of clinical consultations, (iii) emphasizing community-based models and (iv) integrating/aligning with TB preventative therapy (TPT), non-communicable disease (NCD) treatments and family planning commodities. DISCUSSION: Across SSA in 2020, countries both adapted and emphasized policies supporting DSD for HIV treatment in response to COVID-19. Access to DSD for HIV treatment was expanded by reducing the time required on ART before eligibility and being more inclusive of specific populations including children and adolescents, pregnant and breastfeeding women and those on second- and third-line regimens. Access to extended ART refills, or MMD, was accelerated across many countries. A renewed focus was given to out-of-facility community-based models of ART distribution. In some settings, there was acknowledgement of the need to integrate or align other chronic medications with ART. CONCLUSIONS: Adaptations to DSD for HIV treatment in response to COVID-19 have resulted in rapid policy change and in some cases, acceleration of implementation in SSA. As the COVID-19 pandemic evolves, there is a critical need to assess the impact of these adaptations and, where beneficial, ensure that policies implemented in response to COVID-19 become the new normal.
引言:为应对 COVID-19,各国卫生部调整了艾滋病毒服务提供指南,以确保抗逆转录病毒疗法(ART)的不间断供应,并限制与卫生机构的接触频率。在本文中,我们总结了在 COVID-19 期间,撒哈拉以南非洲(SSA)在政策和实施方面加速差异化服务提供(DSD)治疗艾滋病毒的四种方式——(i)扩大 DSD 治疗艾滋病毒的资格,(ii)延长多剂量配药(MMD)并减少临床咨询次数,(iii)强调社区模式,以及(iv)与结核病预防治疗(TPT)、非传染性疾病(NCD)治疗和计划生育商品整合/协调。 讨论:2020 年,整个 SSA 国家都针对 COVID-19 调整并强调了支持 DSD 治疗艾滋病毒的政策。通过减少获得 DSD 治疗艾滋病毒的时间要求,以及更广泛地包括儿童和青少年、孕妇和哺乳期妇女以及二线和三线方案患者等特定人群,扩大了获得 DSD 治疗艾滋病毒的机会。许多国家都加快了延长 ART 续药的机会。对基于社区的 ART 分发的场外模式给予了新的关注。在一些环境中,人们认识到需要将其他慢性药物与 ART 整合或协调。 结论:应对 COVID-19 对 DSD 治疗艾滋病毒的调整导致了政策的快速变化,在某些情况下,加速了 SSA 的实施。随着 COVID-19 大流行的演变,迫切需要评估这些调整的影响,并在有益的情况下,确保应对 COVID-19 实施的政策成为新常态。
PLOS Glob Public Health. 2024-10-16
J Acquir Immune Defic Syndr. 2021-2-1
PLoS Med. 2020-2-14
J Int AIDS Soc. 2017-7-21
J Int AIDS Soc. 2016-12-1